In addition to inducing the degradation of IKZF1/3 proteins, lenalidomide induces the degradation of the neoabstract casein kinase 1α (CK1α), resulting in its approval for the treatment of myelodysplastic syndrome (MDS)208. This evidence concerns the gene IKZF1 and myelodysplastic syndrome.